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EDITORIAL
Cyclooxygenase-2 inhibitors: Will they help us prevent
diabetic nephropathy?
In the past decades, end-stage renal disease (ESRD), diators of inflammatory injury in arthritis and other condi-
tions, and COX inhibition by nonsteroidal anti-inflamma-with the consequent demand for renal replacement ther-
apy (RRT), has evolved into a worldwide medical, social, tory drugs (NSAIDs) has been largely employed in the
treatment of arthritic patients. There is abundant evi-and financial dilemma, which will likely be aggravated
in coming years. Diabetic nephropathy accounts for a dence that COX products mediate inflammation in the
kidneys as well. The synthesis of COX products by culti-large fraction of the new cases of ESRD, an unfortunate
circumstance considering the high frequency of cardio- vated mesangial cells is enhanced by stretching [2], sug-
gesting that they may mediate hemodynamically inducedvascular complications, the early need for RRT, and
the high dialysis-related morbidity that afflicts diabetic renal injury. In addition, COX products may participate
in several immune and nonimmune cellular mechanismsnephropathy patients.
In view of the magnitude of the current ESRD epidem- of renal injury [3]. Up-regulation of both the COX-1
and COX-2 isoforms has been described in experimentalics, no effort should be spared in the struggle to arrest
or at least slow the progression of diabetic and other glomerulopathies, while the production of COX deriva-
tives is increased in the 5/6 renal ablation model [3].progressive nephropathies, thus postponing the need for
RRT. Available treatments include immunosuppressors Accordingly, NSAID treatment attenuated renal injury
in the 5/6 renal ablation model without lowering glomer-(mostly, but not exclusively, for immune-related ne-
phropathies), dietary protein restriction, and, especially, ular pressure, suggesting a purely anti-inflammatory ef-
fect [4].angiotensin-converting enzyme (ACE) inhibitors and
angiotensin II receptor blockers. Although these treat- Several observations reported by Harris et al in the
past 5 years have contributed to elucidate the role ofments have undoubtedly alleviated the social and finan-
cial burden imposed by progressive diabetic and nondia- COX-2 in progressive nephropathies. First, these investi-
betic nephropathies, a substantial fraction of treated gators showed that COX-2 is expressed in the normal
patients still progress to ESRD. Clearly, the develop- rat kidney, particularly at the macula densa region [5].
ment of new renoprotective maneuvers is still badly They next demonstrated that the expression of COX-2
needed. was up-regulated in the 5/6 renal ablation model and
Progressive nephropathies can be initiated by immune that part of the extra COX-2 material located in the
dysfunction, glomerular hemodynamic stress, and toxic glomeruli [6]. In rats with aortic coarctation between the
aggression, among other mechanisms. In diabetic sub- renal arteries, the group showed that COX-2 expression
jects, nonenzymatic protein glycation is also likely to was augmented in the ischemic kidney and that adminis-
play an important role in the pathogenesis of renal injury. tration of a selective COX-2 inhibitor, SC58236, attenu-
There is mounting evidence that, whatever the mecha- ated the systemic hypertension and the hyper-reninemia
nisms that initiate progressive nephropathies, an in- associated with this model [7]. In rats with 5/6 renal
flammatory reaction, involving the recruitment of macro- ablation, administration of the same compound attenu-
phages, lymphocytes, fibroblasts and myofibroblasts, is ated proteinuria and prevented glomerulosclerosis as ef-
required to extend and propagate the initial insult. In- ficiently as enalapril [8], lending further support to the
flammatory cells can be found in the renal tissue prior idea that COX-2 activation plays an important role in
to the establishment of glomerular and interstitial injury the pathogenesis of progressive renal injury.
in several models of chronic nephropathy, including dia- In continuation of this line of investigation, Cheng et
betic nephropathy [1]. Moreover, macrophage depletion al, in a study published in the current issue of Kidney
prevents puromycin-induced renal injury, and treatment International [9], examined a model of experimental dia-
with the anti-lymphocyte agent, mycophenolate mofetil, betes associated with hypertension, in which streptozo-
attenuates renal injury in the renal ablation model [1]. tocin diabetes was combined with deoxycorticosterone
Cyclooxygenase (COX) products are well-known me- (DOCA)-salt treatment. In this model, which mimics
the quite common clinical association of diabetes and
hypertension, glomerular injury progressed at a faster
rate than in rats with diabetes or DOCA-salt alone, re- 2002 by the International Society of Nephrology
1091
Editorial1092
sulting in severe proteinuria and significant glomerulo- failure), have been widely and successfully employed in
the management of progressive nephropathies. If thesclerosis after 6 weeks. The renal expression of COX-2
was increased, along with that of fibronectin, trans- efficacy of COX-2 inhibitors as renoprotective agents is
proven, their clinical use will also have to be governedforming growth factor-beta (TGF-) and plasminogen-
activator inhibitor (PAI-1), suggesting involvement of by careful individual risk/benefit evaluation.
these mediators in the pathogenesis of renal injury in
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